TSHA
Taysha Gene Therapies, Inc.
NASDAQ · Healthcare · Biotechnology · US
$5.60
+0.54%Year over year
Reported trailing growth
- Revenue
- -32.3%
- EBITDA
- -62.6%
- EBIT
- -62.9%
- EPS
- -18.3%
- Free cash flow
- -64.3%
- Operating cash flow
- -61.0%
Forward estimates
Based on analyst estimates
- Revenue
- -28.1%
- EBITDA
- -30.3%
- EPS
- -25.3%
Three-year CAGR
- Revenue
- +57.5%
- EBITDA
- -22.6%
- EBIT
- -20.8%
- Net income
- -22.1%
- EPS
- +5.6%
- Free cash flow
- -15.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026